66 related articles for article (PubMed ID: 38546749)
1. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.
Troschel FM; Troschel BO; Kloss M; Jost J; Pepper NB; Völk-Troschel AS; Wiewrodt RG; Stummer W; Wiewrodt D; Eich HT
Strahlenther Onkol; 2024 Mar; ():. PubMed ID: 38546749
[TBL] [Abstract][Full Text] [Related]
3. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer.
Go SI; Park MJ; Song HN; Kang MH; Park HJ; Jeon KN; Kim SH; Kim MJ; Kang JH; Lee GW
Support Care Cancer; 2016 May; 24(5):2075-2084. PubMed ID: 26546456
[TBL] [Abstract][Full Text] [Related]
5. The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.
Bentahila R; Giraud P; Decazes P; Kreps S; Nay P; Chatain A; Fabiano E; Durdux C
Cancer Med; 2023 Feb; 12(4):4170-4183. PubMed ID: 36263581
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study.
Zhang S; Tan S; Jiang Y; Xi Q; Meng Q; Zhuang Q; Han Y; Sui X; Wu G
Clin Nutr; 2019 Dec; 38(6):2881-2888. PubMed ID: 30630709
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized clinical studies involving reirradiation: update of a systematic review.
Nieder C; Willmann J; Andratschke NH
Strahlenther Onkol; 2023 Sep; 199(9):787-797. PubMed ID: 37500926
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia Is Associated With Aggressive Clinicopathological Outcomes and Is a Poor Prognostic Indicator for Non-metastatic Renal Cell Carcinoma.
Makino T; Izumi K; Iwamoto H; Kadomoto S; Kadono Y; Mizokami A
In Vivo; 2023; 37(3):1304-1311. PubMed ID: 37103104
[TBL] [Abstract][Full Text] [Related]
9. Cervical body composition on radiotherapy planning computed tomography scans predicts overall survival in glioblastoma patients.
Troschel FM; Troschel BO; Kloss M; Troschel AS; Pepper NB; Wiewrodt RG; Stummer W; Wiewrodt D; Eich HT
Clin Transl Radiat Oncol; 2023 May; 40():100621. PubMed ID: 37008514
[TBL] [Abstract][Full Text] [Related]
10. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract][Full Text] [Related]
11. Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Frosina G
Strahlenther Onkol; 2023 Jan; 199(1):1-21. PubMed ID: 36445383
[TBL] [Abstract][Full Text] [Related]
12. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
[TBL] [Abstract][Full Text] [Related]
13. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
